Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 3 | 2013 | 544 | 0.960 |
Why?
|
| Acinetobacter Infections | 2 | 2013 | 28 | 0.880 |
Why?
|
| Acinetobacter baumannii | 2 | 2013 | 52 | 0.870 |
Why?
|
| Wound Infection | 1 | 2022 | 54 | 0.840 |
Why?
|
| Podiatry | 1 | 2021 | 7 | 0.800 |
Why?
|
| Infectious Disease Medicine | 1 | 2021 | 20 | 0.790 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2013 | 202 | 0.790 |
Why?
|
| Communicable Diseases | 1 | 2022 | 193 | 0.720 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 313 | 0.680 |
Why?
|
| Ambulatory Care | 2 | 2022 | 554 | 0.610 |
Why?
|
| Immunization, Passive | 7 | 2023 | 172 | 0.520 |
Why?
|
| Carrier State | 1 | 2012 | 90 | 0.420 |
Why?
|
| Hospitals, Psychiatric | 1 | 2012 | 82 | 0.420 |
Why?
|
| Legionella | 1 | 2012 | 18 | 0.420 |
Why?
|
| Legionellosis | 1 | 2012 | 17 | 0.420 |
Why?
|
| Brain Abscess | 1 | 2012 | 60 | 0.400 |
Why?
|
| Seasons | 1 | 2012 | 340 | 0.380 |
Why?
|
| Infection Control | 1 | 2012 | 270 | 0.380 |
Why?
|
| Endocarditis, Bacterial | 1 | 2012 | 128 | 0.380 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 415 | 0.360 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 308 | 0.350 |
Why?
|
| Prosthesis-Related Infections | 1 | 2012 | 232 | 0.340 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 672 | 0.290 |
Why?
|
| Mental Disorders | 1 | 2012 | 862 | 0.260 |
Why?
|
| Urticaria | 1 | 2023 | 23 | 0.230 |
Why?
|
| JC Virus | 1 | 2023 | 43 | 0.220 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2023 | 46 | 0.220 |
Why?
|
| Transfusion Reaction | 1 | 2023 | 102 | 0.220 |
Why?
|
| West Virginia | 1 | 2021 | 5 | 0.200 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2021 | 12 | 0.200 |
Why?
|
| Foot | 1 | 2021 | 104 | 0.190 |
Why?
|
| Outpatients | 4 | 2023 | 462 | 0.180 |
Why?
|
| Hospitalization | 3 | 2023 | 2083 | 0.160 |
Why?
|
| Wound Healing | 1 | 2022 | 815 | 0.150 |
Why?
|
| Skin | 1 | 2022 | 1259 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 2992 | 0.130 |
Why?
|
| Risk Factors | 3 | 2021 | 17523 | 0.130 |
Why?
|
| Humans | 18 | 2023 | 261506 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2013 | 6100 | 0.110 |
Why?
|
| Skin Diseases, Infectious | 1 | 2012 | 22 | 0.110 |
Why?
|
| Pennsylvania | 1 | 2012 | 64 | 0.110 |
Why?
|
| Endocardium | 1 | 2012 | 50 | 0.100 |
Why?
|
| Ofloxacin | 1 | 2012 | 41 | 0.100 |
Why?
|
| Nursing Homes | 1 | 2012 | 99 | 0.100 |
Why?
|
| Levofloxacin | 1 | 2012 | 57 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2012 | 106 | 0.100 |
Why?
|
| Medical Audit | 1 | 2012 | 188 | 0.100 |
Why?
|
| Patient Admission | 1 | 2012 | 220 | 0.100 |
Why?
|
| Bacteriological Techniques | 1 | 2012 | 121 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 980 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 1323 | 0.090 |
Why?
|
| Aged | 4 | 2021 | 70117 | 0.090 |
Why?
|
| Catheterization, Central Venous | 1 | 2012 | 354 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 330 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2012 | 583 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 672 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2012 | 627 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 399 | 0.080 |
Why?
|
| Deglutition Disorders | 1 | 2012 | 447 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2012 | 437 | 0.080 |
Why?
|
| Middle Aged | 4 | 2021 | 86204 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 678 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 589 | 0.080 |
Why?
|
| Radiography | 1 | 2012 | 1904 | 0.070 |
Why?
|
| Neoplasms | 1 | 2013 | 15193 | 0.070 |
Why?
|
| Male | 5 | 2023 | 123000 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2023 | 2588 | 0.070 |
Why?
|
| Critical Care | 1 | 2012 | 770 | 0.070 |
Why?
|
| Adult | 6 | 2023 | 77950 | 0.070 |
Why?
|
| Echocardiography | 1 | 2012 | 1182 | 0.070 |
Why?
|
| Female | 5 | 2023 | 141928 | 0.070 |
Why?
|
| United States | 4 | 2023 | 15433 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 2594 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2021 | 37905 | 0.060 |
Why?
|
| Cytokines | 2 | 2023 | 2809 | 0.060 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2023 | 12 | 0.060 |
Why?
|
| Interleukin-7 | 1 | 2023 | 95 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2022 | 32848 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2023 | 519 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 838 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 222 | 0.050 |
Why?
|
| Syndrome | 1 | 2023 | 1351 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2023 | 1038 | 0.040 |
Why?
|
| Brain | 1 | 2012 | 4113 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 1533 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2023 | 3203 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 1320 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 7702 | 0.030 |
Why?
|
| Young Adult | 1 | 2012 | 21445 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 2522 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 29902 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1559 | 0.030 |
Why?
|
| Adolescent | 2 | 2023 | 31252 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 6682 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 4367 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 12873 | 0.020 |
Why?
|